Pharmaceutical companies will be legally required to continue paying for patient treatments after clinical trials end
Effective this Friday, 23 October, a new ministerial order legally mandates that pharmaceutical companies must continue to provide and fund treatments for patients who participated in clinical trials after those trials conclude. While this practice was already common, it is now a formal legal safeguard.

